# IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

> **NCT03705403** · PHASE2 · TERMINATED · sponsor: **Maastricht University Medical Center** · enrollment: 88 (actual)

## Conditions studied

- NSCLC Stage IV
- Metastatic Disease

## Interventions

- **DRUG:** Darleukin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03705403
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-04
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-01-06
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03705403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03705403, "IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03705403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*